Search

Your search keyword '"Carmody, Thomas J."' showing total 317 results
Start Over Author "Carmody, Thomas J."
317 results on '"Carmody, Thomas J."'

3. Sexual orientation differences among men in a randomized clinical trial of extended-release naltrexone and bupropion for methamphetamine use disorder

Author

Kidd, Jeremy D, Smiley, Sabrina L, Coffin, Phillip O, Carmody, Thomas J, Levin, Frances R, Nunes, Edward V, Shoptaw, Steven J, and Trivedi, Madhukar H

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Methamphetamine, Substance Misuse, HIV/AIDS, Clinical Trials and Supportive Activities, Sexual and Gender Minorities (SGM/LGBT*), Sexually Transmitted Infections, Clinical Research, Infectious Diseases, 6.1 Pharmaceuticals, Humans, Male, Female, Naltrexone, Bupropion, Homosexuality, Male, Prospective Studies, Sexual and Gender Minorities, Sexual Behavior, Double-Blind Method, Gay, Bisexual, Stimulants, Addiction, Psychopharmacology, Medical and Health Sciences, Psychology and Cognitive Sciences, Substance Abuse, Biochemistry and cell biology, Pharmacology and pharmaceutical sciences, Epidemiology
Abstract

BackgroundMethamphetamine use disorder (MethUD) disproportionately affects men who have sex exclusively with men or with men and women (collectively MSM/W), compared to men who have sex with women (MSW). This study is the first MethUD medication trial to compare treatment effect for these groups, hypothesizing that extended-release injectable naltrexone 380mg every 3 weeks plus oral extended-release bupropion 450mg daily would be less effective for MSM/W than MSW.MethodsData come from men (N = 246) in a multi-site, double-blind, randomized, placebo-controlled trial with sequential parallel comparison design. In Stage 1 (6-weeks), participants were randomized to active treatment or placebo. In Stage 2 (6-weeks), Stage 1 placebo non-responders were rerandomized. Treatment response was ≥3 methamphetamine-negative urine samples, out of four obtained at the end of Stages 1 and 2. Treatment effect was the active-versus-placebo between-group difference in the weighted average Stages 1 and 2 responses.ResultsMSM/W (n = 151) were more likely than MSW (n = 95) to be Hispanic, college-educated, and living with HIV. Adjusting for demographics, among MSM/W, response rates were 13.95 % (active treatment) and 2.78 % (placebo) in Stage 1; 23.26 % (active treatment) and 4.26 % (placebo) in Stage 2. Among MSW, response rates were 7.69 % (active treatment) and 5.80 % (placebo) in Stage 1; 3.57 % (active treatment) and 0 % (placebo) in Stage 2. Treatment effect was significantly larger for MSM/W (h = 0.1479) than MSW (h = 0.0227) (p = 0.04).ConclusionsFindings suggest efficacy of extended-release naltrexone plus bupropion for MSM/W, a population heavily burdened by MethUD. While a secondary outcome, this intriguing finding merits testing in prospective trials.

Published
2023

6. Neural substrates of emotional conflict with anxiety in major depressive disorder: Findings from the Establishing Moderators and biosignatures of Antidepressant Response in Clinical Care (EMBARC) randomized controlled trial

Author

Trombello, Joseph M., Cooper, Crystal M., Fatt, Cherise Chin, Grannemann, Bruce D., Carmody, Thomas J., Jha, Manish K., Mayes, Taryn L., Greer, Tracy L., Yezhuvath, Uma, Aslan, Sina, Pizzagalli, Diego A., Weissman, Myrna M., Webb, Christian A., Dillon, Daniel G., McGrath, Patrick J., Fava, Maurizio, Parsey, Ramin V., McInnis, Melvin G., Etkin, Amit, and Trivedi, Madhukar H.

Published
2022
Full Text
View/download PDF

10. Anxiety and anhedonia in depression: Associations with neuroticism and cognitive control

Author

Liao, Allen, Walker, Robrina, Carmody, Thomas J., Cooper, Crystal, Shaw, Meredith A., Grannemann, Bruce D., Adams, Phil, Bruder, Gerard E., McInnis, Melvin G., Webb, Christian A., Dillon, Daniel G., Pizzagalli, Diego A., Phillips, Mary L., Kurian, Benji T., Fava, Maurizio, Parsey, Ramin V., McGrath, Patrick J., Weissman, Myrna M., and Trivedi, Madhukar H.

Published
2019
Full Text
View/download PDF

13. Characterizing anxiety subtypes and the relationship to behavioral phenotyping in major depression: Results from the EMBARC study

Author

Trombello, Joseph M., Pizzagalli, Diego A., Weissman, Myrna M., Grannemann, Bruce D., Cooper, Crystal M., Greer, Tracy L., Malchow, Ashley L., Jha, Manish K., Carmody, Thomas J., Kurian, Benji T., Webb, Christian A., Dillon, Daniel G., McGrath, Patrick J., Bruder, Gerard, Fava, Maurizio, Parsey, Ramin V., McInnis, Melvin G., Adams, Phil, and Trivedi, Madhukar H.

Published
2018
Full Text
View/download PDF

16. Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design

Author

Trivedi, Madhukar H., McGrath, Patrick J., Fava, Maurizio, Parsey, Ramin V., Kurian, Benji T., Phillips, Mary L., Oquendo, Maria A., Bruder, Gerard, Pizzagalli, Diego, Toups, Marisa, Cooper, Crystal, Adams, Phil, Weyandt, Sarah, Morris, David W., Grannemann, Bruce D., Ogden, R. Todd, Buckner, Randy, McInnis, Melvin, Kraemer, Helena C., Petkova, Eva, Carmody, Thomas J., and Weissman, Myrna M.

Published
2016
Full Text
View/download PDF

21. A Psychometric Evaluation of the CDRS and MADRS in Assessing Depressive Symptoms in Children

Author

Jain, Shailesh, Carmody, Thomas J., and Trivedi, Madhukar H.

Abstract

Objective: This study compared the psychometric properties of the Children's Depression Rating Scale-Revised (CDRS-R) and the Montgomery-Asberg Depression Rating Scale (MADRS) in children with major depressive disorder. Method: Children (N = 96; ages 8 to 11 years inclusive) with nonpsychotic major depressive disorder were enrolled. Participants were part of a multisite, outpatient, randomized, placebo-controlled, 9-week trial of fluoxetine (10 mg/day for the first week and 20 mg/day thereafter). The CDRS-R and MADRS were completed based on clinician interviews with both parents and children. Classic test theory and item response theory analyses were conducted. Results: The MADRS and CDRS-R total scores were correlated at baseline (r = 0.51) and at study exit (r = 0.85). Cronbach's [alpha] was 0.86 (CDRS-R) and 0.82 (MADRS) at exit. The effect sizes for change from baseline to exit between the fluoxetine and placebo groups were 0.78 (CDRS-R) and 0.61 (MADRS). There was agreement between the CDRS-R and MADRS in the declaration of treatment response (50% improvement from baseline to exit) in 84.2% of children. Test information function favored the CDRS-R. Conclusions: The CDRS-R showed greater effect size for differentiating drug and placebo and better test information than the MADRS in this study of depressed children. (Contains 1 figure and 6 tables.)

Published
2007

22. The Concise Health Risk Tracking ‐ Self‐Report (CHRT‐SR)—A measure of suicidal risk: Performance in adolescent outpatients.

Author

Nandy, Karabi, Rush, A. John, Carmody, Thomas J., Kulikova, Alexandra, Mayes, Taryn L., Emslie, Graham, and Trivedi, Madhukar H.

Subjects
CLASSICAL test theory, ITEM response theory, SELF-evaluation, PSYCHOMETRICS, CONFIRMATORY factor analysis
Abstract

Objectives: The Concise Health Risk Tracking Self‐Report (CHRT‐SR) assesses the risk of suicidal behavior. We report its psychometric properties in a representative sample of adolescent outpatients. Methods: A sample (n = 657) of adolescents (<18 years of age) in primary or psychiatric care completed the 14‐item version of CHRT‐SR at both baseline and within 3 months. To identify an optimal brief solution for the scale, we evaluated the factor structure of CHRT‐SR using multigroup confirmatory factor analysis, and testing measurement invariance across age and gender. The item response theory and classical test theory characteristics of the optimal solution were evaluated. Concurrent validity (both cross‐sectional and as a change measure over time) of the optimal solution was assessed by comparing it to another suicide measure. Results: Confirmatory factor analysis identified the 9‐item CHRT‐SR (CHRT‐SR9) as the optimal solution. Classical test theory and item response theory indicated excellent fit. Concurrent validity analyses revealed that it can measure both improvement/worsening of suicidality over time. Conclusion: The CHRT‐SR9 is a brief self‐report with excellent psychometric properties in a sample of adolescents that is sensitive to changes in suicidality over time. Its performance in other populations and ability to predict future suicidal events deserves study. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

42. Comparing the smoking behavior of veterans and nonveterans

Author

McKinney, W. Paul, McIntire, Donald D., Carmody, Thomas J., and Joseph, Anne

Subjects
Veterans, Smoking -- Sex differences
Abstract

Until the mid-1990s, data on the smoking behavior of veterans were available only for small populations in select settings. Reports described the prevalence of smoking among outpatients as ranging between […]

Published
1997

Catalog

Books, media, physical & digital resources
See catalog results